Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2025-09-08 00:00:00 ET · period of report 2025-09-04 · accession 0001415889-25-023893 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-09-08 | 2025-09-04 | MLYS | RA CAPITAL MANAGEMENT, L.P. | Dir | P - Purchase | $25.50 | +1.18M | 5.46M | +27% | +$30.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-04 | P | A | 1,176,470 | $25.50 | 5,456,521 | I See footnotes | — | — | (F1) Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |